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Following publication of the original article \[[@CR1]\], the authors identified errors in Fig. [1](#Fig1){ref-type="fig"}. The legends in Fig. [1](#Fig1){ref-type="fig"}c and d refer to placebo, baricitinib 4-mg and adalimumab treatment groups; the legends should refer to placebo, baricitinib 2-mg, and baricitinib 4-mg and the reference to these two studies in the figure caption are reversed. Additionally, the total number of interruptions for baricitinib 4-mg in RA-BEAM (Fig. [1](#Fig1){ref-type="fig"}b) has been corrected from 82 to 62 and the title for RA-BEAM has been corrected from 0-52 weeks to 0-24 weeks; labels have been corrected for MTX (8--14 days) in RA-BEGIN from 28 to 29 and for placebo (15--21 days) in RA-BUILD from 17 to 16.

The corrected Fig. [1](#Fig1){ref-type="fig"} is given below. Fig. 1Duration of interruptions in the phase 3 studies RA-BEGIN (**a**), RA-BEAM (**b**), RA-BEACON (**c**), and RA-BUILD (**d**)^a,b^. ^a^Interruptions are based on daily tablet baricitinib study drug, including in non-baricitinib groups, which represent interruptions of the matching placebo for baricitinib. ^b^Temporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study. MTX, methotrexate
